Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx

被引:64
作者
Song, Ning [1 ]
Jiang, Hong [1 ]
Wang, Jun [1 ]
Xie, Jun-Xia [1 ]
机构
[1] Qingdao Univ, Dept Physiol, Coll Med, Qingdao 266071, Peoples R China
关键词
divalent metal transporter 1; ferrous iron; 6-hydroxydopamine; Parkinson's disease; substantia nigra;
D O I
10.1002/jnr.21430
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The reasons underlying the high iron content found in the substantia nigra (SN) of Parkinson's disease (PD) are largely unknown. We suppose, based on our previous studies, that the newly discovered iron transporter divalent metal transporter 1 (DMT1) might be involved in this SN iron accumulation process. To investigate this, we first observed the cellular expression of DMT1 in rat SN, both with the iron response element (+IRE) and without the IRE (-IRE) forms. The results showed that both forms of DMT1 were expressed on neurons, astrocytes, and microglia but not on oligodendrocytes. We further observed the relationship between the increased iron influx and DMT1 expression in 6-hydroxydopamine (6-OHDA)-treated C6 cells. 6-OHDA (10 mu mol/liter) caused a significant increase in ferrous iron influx, with the increased expression of DMT1 +IRE, both in protein and in mRNA levels, whereas no change was observed for DMT1 -IRE. To clarify further that the increased expression of DMT1 was not due to the increased intracellular iron content, C6 cells were overloaded with ferric ammonium citrate (100 mu g/ml). Decreased expression of both forms of DMT1 was observed. Our data suggest that DMT1 is highly expressed in rat SN in a cell-specific manner. Increased DMT1 +IRE expression is the mechanism behind ferrous iron influx induced by 6-OHDA treatment in C6 cells. This may give some evidence for the involvement of DMT1 in the iron accumulation in PD. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:3118 / 3126
页数:9
相关论文
共 44 条
[1]   Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats [J].
Ben Shachar, D ;
Kahana, N ;
Kampel, V ;
Warshawsky, A ;
Youdim, MBH .
NEUROPHARMACOLOGY, 2004, 46 (02) :254-263
[2]   In vivo detection of iron and neuromelanin by transcranial sonography - a new approach for early detection of substantia nigra damage [J].
Berg, D. .
JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (06) :775-780
[3]   Iron metabolism in parkinsonian syndromes [J].
Berg, Daniela ;
Hochstrasser, Helmine .
MOVEMENT DISORDERS, 2006, 21 (09) :1299-1310
[4]   Extracellular toxicity of 6-hydroxydopamine on PC12 cells [J].
Blum, D ;
Torch, S ;
Nissou, MF ;
Benabid, AL ;
Verna, JM .
NEUROSCIENCE LETTERS, 2000, 283 (03) :193-196
[5]   IRON ACQUIRED FROM TRANSFERRIN BY K562 CELLS IS DELIVERED INTO A CYTOPLASMIC POOL OF CHELATABLE IRON(II) [J].
BREUER, W ;
EPSZTEJN, S ;
CABANTCHIK, ZI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (41) :24209-24215
[6]  
Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256.abs
[7]   Separate pathways for cellular uptake of ferric and ferrous iron [J].
Conrad, ME ;
Umbreit, JN ;
Moore, EG ;
Hainsworth, LN ;
Porubcin, M ;
Simovich, MJ ;
Nakada, MT ;
Dolan, K ;
Garrick, MD .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2000, 279 (04) :G767-G774
[8]  
Double KL, 1998, J NEUROCHEM, V70, P2492
[9]   Iron regulatory proteins and the molecular control of mammalian iron metabolism [J].
Eisenstein, RS .
ANNUAL REVIEW OF NUTRITION, 2000, 20 :627-662
[10]   DISTRIBUTION OF I-125 FERROTRANSFERRIN BINDING-SITES IN THE MESENCEPHALON OF CONTROL SUBJECTS AND PATIENTS WITH PARKINSONS-DISEASE [J].
FAUCHEUX, BA ;
HIRSCH, EC ;
VILLARES, J ;
SELIMI, F ;
MOUATTPRIGENT, A ;
JAVOYAGID, F ;
HAUW, JJ ;
AGID, Y .
JOURNAL OF NEUROCHEMISTRY, 1993, 60 (06) :2338-2341